Kornimate/medical-research-clean huggingface dataset:
endovascular treatment for chronic cerebrospinal venous insufficiency (ccsvi)

Conditions: Multiple Sclerosis

Summary: the aim of this study is to assess the efficacy of endovascular treatment (balloon angioplasty and/or stenting) for the improvement of clinical symptoms in multiple sclerosis patients.

the aim of this study is to assess the efficacy of endovascular treatment (balloon angioplasty and/or stenting) for the improvement of clinical symptoms in multiple sclerosis patients measured by extended disability severity score (edss), multiple sclerosis impact scale-29 (msis-29), fatigue severity scale (fss) and heat intolerance

Eligibility criteria:
inclusion criteria: * patients with clinically defined multiple sclerosis exclusion criteria: * contraindication for endovascular procedure performed in local anesthesia

Keywords: multiple sclerosis venous insufficiency
fluctuation of rhymicity to predict recovery

Conditions: Coma

Summary: brief summary : in the most severe cases of brain injuries, intensive care may allow patients with altered consciousness to survive despite a significant risk of heavy sequelae. persistent impairments of consciousness are currently categorized according to behavior in three main neurological categories: comatose state, vegetative state (recently named unresponsive wakefulness syndrome) and minimally conscious state. refining the diagnosis of internal state is a major goal to determine the abilities for an optimal recovery of cognitive deficit. circadian rhythms are implicated in the regulation of sleep-wake cycles but also in cognitive functions. their role is actually revaluated in the mechanisms of consciousness impairment. first, it is well known that cognitive performances partially depend on such rhythms as they are more elevated during the day and correlated to the hormonal secretion. in a prognostic point of view, fewer rhythmic perturbations during the initial resuscitation period (with reorganized sleep rhythms and the presence of paradoxical sleep) could be associated to a higher functional outcome. however, this internal state of alertness could be highly variable during the day as it might be influenced by specific rhythms such as the circadian rhythm. only a continuous assessment could help defining them properly. thus, investigators hypothesize that the circadian restauration, assessed in a dynamic perspective, is associated with the improvement of content and level of awareness. the main challenge of our study is to capture the long-term changes in the evolution of circadian and ultradian rhythms and to keep a part of the natural history of the clinical recovery of these patients. to achieve this goal, the investigators plan to analyze during more than 2 days both neurophysiological rhythms (eeg) and behavioral rhythms of alertness ("eyes" scale from of the glasgow coma scale) in a dataset collected retrospectively from the population of patients continuously monitored by eeg for medical purposes (to identify seizures and prevent status epilepticus) in an intensive care unit of teaching hospital as far as acquisitions last more than 48h and present no prolonged epileptic discharges or artifacts leading to uninterpretable egg.


Eligibility criteria:
inclusion criteria: * adult patient * admitted in icu * altered level of consciousness not explained by a continuous sedation * eeg during more than 48h consecutively exclusion criteria: * prolonged epileptic discharges leading to uninterpretable eeg rhythms * prolonged artifacts leading to uninterpretable eeg trace
exploring telehealth to deliver me & my wishes during coronavirus-19

Conditions: Health Communication

Summary: due to coronavirus-19, we are exploring the plausibility of delivering the me \& my wishes intervention via telehealth.

me \& my wishes are videos of nursing home residents talking about their preferences for care, including four sections: about me, preferences for today, preferences for medical intervention and end of life, and afterthoughts. knowing what residents want is essential to staff's ability to provide quality care and can inform family caregivers decision making especially in later stages of life as the resident's cognition declines-a time when family caregivers often feel unprepared. persons with mild to moderate dementia can accurately express their everyday and end of life preferences, however, stereotypes persist about the decision making abilities of people with dementia that often prevent their involvement in conversations about care. the investigators propose to explore the feasibility of delivering me \& my wishes via a telehealth platform.

Eligibility criteria:
resident inclusion criteria: * identified as having alzheimer's or related dementia * mild to moderate cognitive impairment (bims = 8-15, (mds c0500) (nursing home residents only) * makes self understood = \<1 (mds b0700)/present in medical record * understood by others = \<1 (mds b0800)/present in medical record * reside at the facility at least 2 weeks identified as a long-term resident * age \>65 years * speaks english family inclusion criteria: * speaks english * willing and able to watch the videos * willing to complete short surveys. being unable to attend care conference to view the video (e.g. due to distance) will not exclude family from participating. staff inclusion criteria: * speaks english * willing to watch the videos * willing to complete short surveys resident exclusion criteria: * limited communication capacity (e.g. aphasia) * comatose * cognitively intact * severe cognitive impairment
a phase i study to assess the electrophysiologic effects of bms-394136 on the atrium and ventricle in patients with dual-chamber pacemakers or defibrillators

Conditions: Heart Diseases

Summary: double-blind, randomized, single-dose study to evaluate the atrial selectivity and safety of bms-394136 in subjects with implanted dual-chamber pacemakers or defibrillators


Eligibility criteria:
inclusion criteria: * patients with dual-chamber pacemakers or defibrillators exclusion criteria: * recent acute ischemic events * recent atrial or ventricular arrhythmias * uncompensated heart failure * amiodarone use within last year * women of childbearing potential * qtc \<430 msec males * qtc \<450 msec females

Keywords: patients requiring dual-chamber pacemakers or defibrillators
quantification of motor function in infants with spinal muscular atrophy treated with innovative therapies

Conditions: Spinal Muscular Atrophy

Summary: the aim of the study is to propose a method for quantifying motor function in infants with spinal muscular atrophy treated with innovative therapies using inertial sensors.

infantile spinal muscular atrophy is a common disease (the second most common fatal autosomal recessive disease after cystic fibrosis), neurodegenerative disorders of childhood causing severe motor impairment and a risk to life through respiratory failure in the most severe forms. innovative therapies (gene therapy or pharmacogenetics) have recently proven their effectiveness on survival criteria. nevertheless, the motor benefit of these therapies must be evaluated more precisely. currently, the reference methods for motor development assessment are fairly robust semi-quantitative motor scales that lack sensitivity and do not reflect function (chopintend, hine, bayley scale, mfm and cgi-scale). advances in recent techniques have enabled the emergence of non-invasive, secure, easy-to-use inertial sensors in routine clinical practice that allow quantification of infant movements. the aim of the study is to propose a method for quantifying motor function in infants with spinal muscular atrophy treated with innovative therapies using inertial sensors.

Eligibility criteria:
inclusion criteria: * infants of both sexes * suffering from spinal muscular atrophy (diagnosis by genetic study "homozygous deletion of smn1") * followed up by the necker neuromuscular reference center (gnmh) * eligible for innovative therapy (gene therapy or pharmacogenetics) * age of onset of the disease \<1 year * no severe respiratory impairment (dependence on ventilatory support for more than 16 hours per day) or bulbar involvement * decision of treatment by a multidisciplinary consultation meeting national of experts * benefiting from social security scheme * informed consent signed by holders of parental authority and the investigator exclusion criteria: * non-consent of one of the holders of parental authority * respiratory instability (dependence on ventilatory support for more than 16 hours per day) or hemodynamics * contraindication to innovative therapy * history of another disease impacting motor skills (neonatal suffering, etc.)

Keywords: spinal muscular atrophy innovative therapies motor function wearable inertial sensors
international registry for intraductal papillary mucinous neoplasma

Conditions: Pancreatic Cysts

Summary: a centralized web-based database will be used to track patients with ipmn lesions of the pancreas to study natural history and risk factors for malignant transformation in this multi-center study.

intraductal papillary mucinous neoplasms of the pancreas (ipmn) are increasingly recognized in clinical practice. they represent a unique clinicopathologic entity that is characterized by mucin production, cystic dilation of the pancreatic ducts, and intraductal papillary growth. the world health organization recognized ipmn as a distinct clinical entity in 1996. recent literature suggests that up to 45% of ipmn are malignant and should be resected; however these data are based on larger, primarily symptomatic lesions. several studies have been published in the recent literature reporting single-center experience with ipmn resections and observations with small numbers of patients. the natural history of these lesions and risk of malignancy is still vague. consensus guidelines for management of ipmn were published in 2006, but noted the limited knowledge available in six areas: definition and classification, preoperative evaluation, indication for resection, method of resection, histological data on frozen section/positive margins and specimen processing, and finally, method of follow-up. speaking to this need, we propose an international registry for multi-center collaboration in the above areas of need in ipmn research and clinical management. this will be through a centralized, web-based registry with data entered by each center in a de-identified way to protect confidentiality. the data collected from the irb approved retrospective chart review irb# 07-007202 will be incorporated into this data base. any patients that participate in the prospective study will be consented with hippa consent prior to collection of data.

Eligibility criteria:
inclusion criteria: * suspected ipmn based on the consensus guidelines (7) * endoscopic ultrasound imaging at baseline examination * either surgical histology or clinical follow up with eus, mri, or ct scan for at least 1 year * cases previously collected that meet the above criteria will be allowed exclusion criteria: * patients who do not meet the above inclusion criteria
metformin for the prevention of the metabolic side-effects of zyprexa

Conditions: Metabolic Complications

Summary: we hypothesize that metformin co-administered with olanzapine will be well tolerated and associated with significantly less insulin resistance, weight gain and dyslipidemia as compared to olanzapine plus placebo.

increased risk of metabolic complications with olanzapine therapy, relative to other antipsychotics, may lead clinicians to avoid its use, despite evidence of greater efficacy. these problems may also pose a therapeutic dilemma for patients who respond well to olanzapine. metabolic complications negatively impact on morbidity and mortality, impair quality of life and increase illness relapse secondary to medication non-compliance. thus far, no pharmacologic agent co-administered with olanzapine has proven effective at preventing these untoward effects. the present study proposes to examine the efficacy and safety of metformin to attenuate the metabolic side effects associated with olanzapine.

Eligibility criteria:
inclusion criteria: * diagnosis of: schizophrenia, schizoaffective disorder, bipolar i or ii or major depression with psychotic features who will be started on or who have just started taking olanzapine (zyprexa). exclusion criteria: * patients with either a history of diabetes mellitus or a baseline fbg\>126 or two random blood sugars of \> 200 or during a ogtt glucose level of \> 200 two hours after a glucose load of 50 grams. (all american diabetes association criteria for diabetes mellitus). * baseline liver function tests (sgot, sgpt, ap) greater than 3x normal. * chronic alcoholism * mdrd less than 60 ml/1.73 m2. modification of diet in renal disease (mdrd) equation estimates the glomerular filtration rate as a measure of kidney function. this equation takes into account the plasma creatinine, age, race and gender, and is a more accurate estimation of glomerular filtration rate than serum creatinine alone. * patients with unstable medical problems, including cardiovascular instability or significant congestive heart failure (as determined by study investigators). * prolonged qtc greater than 430 ms on baseline ekg. * history of lactic acidosis. * history of hypoglycemia. * current treatment with metformin or other antidiabetic agents. * treatment with any antihyperlipidemic medication within 3 months of randomization. * treatment with olanzapine or clozapine within 3 months of randomization. * concurrent treatment with ziprasidone, risperidone, quetiapine or aripiprazole or any other neuroleptic medication. * concurrent use of otc chromium, gymnema or cimetidine will be prohibited. patient may discontinue these medications up to one day prior to randomization. * current treatment with corticosteroids.

Keywords: olanzapine zyprexa weight gain antipsychotics metformin glucophage bipolar disorder schizophrenia depression diabetes side effects metabolic complications prevention treatment metabolic side effects of olanzapine
cytomegalovirus hyperimmune globulin (cmv-ig) replacement in hypogammaglobulinemic lung transplant recipients

Conditions: Hypogammaglobulinemia

Summary: this is a randomized controlled trial of cmv-ig in lung transplant recipients at the cleveland clinic foundation who are hypogammaglobulinemic.

this is a randomized controlled trial of cmv-ig in lung transplant recipients at the cleveland clinic foundation who are hypogammaglobulinemic.

Eligibility criteria:
inclusion criteria: * lung transplant * hypogammaglobulinemia

Keywords: lung transplantation
normal saline versus betadine use to reduce the incidence of wound infection in cesarean section

Conditions: Incidence of cs Scar Infection

Summary: this is a prospective randomized controlled study to the difference between using normal saline or betadine irrigation of wound prior to skin closure in reducing the incidence of wound infection after cesarean section.

this study will be conducted at the department of obstetrics \& gynecology, kasr el-ainy teaching hospital, faculty of medicine, cairo university, from february to july 2018. we include in our study 3oo pregnant women who will undergo cesarean section. all participants will be divided into 3 groups with a 1:1:1 ratio with 100 patients in each group. each participant will provide an informed written consent. consenting patients will be pre-operatively randomised using numerically ordered cards in sealed envelopes to either the group 1 (wound irrigation with 100 ml of normal saline before skin closure) or the group 2 (wound irrigation with 50 ml of 10% aqueous povidone iodine solution ̋ betadinȅ ) or the control group (no wound irrigation with normal saline nor betadine).subjects candidate for the study will be 37 weeks' gestation and require a cesarean section (elective or emergency). patients with allergy to iodine, history of immunosuppressive drug use, gestationaldiabetes mellitus or preeclampsia, anemic patients, ruptured of membranes and feverish patients will be excluded from the study. the primary outcome will be the incidence of wound infection. wound infection is diagnosed when the wound drained purulent material or serosanguineous fluid in association with induration, warmth and tenderness. suspected wound infections are opened for confirmation and wound cultures will be taken. haematoma, seroma, or wound breakdown in the absence of the previouslydiscussed signs is not considered a wound infection.wounds are examined twice daily during hospitalization for evidence of infection. after discharge, the women are instructed on the signs and symptoms of wound infection, and asked to contact one of the co-authors immediately if any of the listed symptoms appeared. all participants are examined at 2 and 6 weeks after surgery.

Eligibility criteria:
inclusion criteria: * subjects candidate for the study will be 37 weeks' gestation * require a cesarean section (elective or emergency). exclusion criteria: * patients with allergy to iodine * history of immunosuppressive drug use, * gestationaldiabetes mellitus * preeclampsia * anemic patients * ruptured of membranes * feverish patients

Keywords: saline, betadine, cesarean scar infection
left-atrium-appendage occluder register - germany

Conditions: Atrial Fibrillation; Stroke

Summary: * evaluation of safety and effectiveness of implantable laa occluder in clinical practice * indication: for which reasons is the indication for implantation of laa-occluder put for patients with atrial fibrillation? * safety: how save is the implantation of laa-occluders? * effectiveness: how effective is implantation of laa-occluders in daily clinical practice? * concomitant treatment: which concomitant treatment is prescribed for patients with laa-occluder?

laarge aims to show the care reality of patients whose left atrial appendage (laa) is closed by an implantable medical device. in particular the following questions should be answered: * indication: for which reasons is the indication for implantation of laa-occluder put for patients with atrial fibrillation? * safety: how save is the implantation of laa-occluders (procedural, in hospital and in the long term course)? how frequent are bleeding complications and what is the relation of observed and expected bleeding complications (according has-bled score)? * effectiveness: how effective is implantation of laa-occluders in daily clinical practice (in hospital and in the long term course)? how frequent are strokes and what is the relation of observed and expected strokes (according chads-vasc score)? * concomitant treatment: which concomitant treatment is prescribed for patients with laa-occluder?

Eligibility criteria:
inclusion criteria: intention to laa occluder exclusion criteria: missing informed consent

Keywords: laa laa-occluder atrial fibrillation af
tak-242 in patients with acute alcoholic hepatitis

Conditions: Acute-On-Chronic Liver Failure

Summary: a phase 2a double-blind, randomized, placebo-controlled, multicenter, proof-of-concept study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of tak-242 in subjects with acute decompensation of alcohol-related cirrhosis due to alcoholic hepatitis resulting in acute-on-chronic liver failure.


Eligibility criteria:
inclusion criteria: * history of alcohol-related cirrhosis who continue to drink heavily * history of an acute decompensating event with a clinical and/or liver biopsy diagnosis of alcoholic hepatitis * grade 1 or 2 aclf using the clif-c of score; or bilirubin criteria or criteria of acute kidney injury stage 1b or 2 after initial supportive treatment with fluids, albumin, or terlipressin; and clif-c aclf score is \>35 and \<64 * history of alcohol-related cirrhosis based on clinical, radiological, and/or histological evidence exclusion criteria: * received certain previous therapies (any investigational drug within 30 days of randomization, corticosteroids for alcohol-induced liver failure within 4 weeks of randomization, or received tak-242 in any previous study) * history of liver cirrhosis from other chronic diseases; liver failure from other causes * history of liver transplantation, post-operative decompensation after partial hepatectomy, acute or subacute liver failure without underlying cirrhosis * any untreated infections including gram-positive infections, or active or latent atuberculosis, sepsis or septic shock, or coinfection with hepatitis b virus, hepatitis c virus, hepatitis e virus, or hiv * chronic or pre-existing kidney failure, uncontrolled medical disorder that might confound study results or compromise subject safety, oxygen saturation \<90%, or requires mechanical ventilation. * uncorrected anemia, methemoglobinemia, disseminated intravascular coagulation, significant or uncontrolled bleeding, atypical laboratory screening tests. * uncontrolled seizures, grade 3 or 4 hepatic encephalopathy, creutzfeldt-jakob disease, glucose-6-phosphate dehydrogenase deficiency. * active extrahepatic malignancy or survival prognosis of \<6 months.
accuracy of pulse pressure variation and of pleth variability index to predict the response to a fluid challenge

Conditions: Fluid Responsiveness

Summary: the aim of this study is to compare the accuracy of pleth variability index (radical 7 device) and of pulse pressure variation (nexfin device) with the doppler measurement of stroke volume (esophageal doppler) to detect the response to a fluid challenge.


Eligibility criteria:
inclusion criteria: * patients undergoing major abdominal surgical procedures performed by laparotomy * patients undergoing major urological surgical procedures performed by laparotomy * patients undergoing major gynecological surgical procedures performed by laparotomy * age ≥ 18 years * signed informed consent exclusion criteria: * pregnant women * esophageal disease * aortic valve disease * allergy to gelatin * bmi \> 35 * beta blocker treatment, antiarrhythmic treatment, arrhythmia, pace-maker, * presence of an arterio-venous shunt or of any other vascular disease on upper limb
real world study of the effectiveness and safety of conbercept ophthalmic injection in the treatment of retinopathy of prematurity - multicenter, retrospective and observational study based on real world data

Conditions: Retinopathy of Prematurity

Summary: this study is a retrospective, multi-center real world study. the real world data comes from the electronic medical record system and disease database of the research centers .the patient's demographic information, disease information, clinical treatment status, efficacy evaluation and adverse events and so on will be collected and evaluated by applicability of the data, generated an analysis data set. use the causal inference method of statistical analysis to observe the effectiveness and safety of intravitreal injection of conbercept, and explore the effectiveness and safety of different doses in the treatment of retinopathy of prematurity.


Eligibility criteria:
inclusion criteria: 1. patient who are diagnosed as retinopathy of prematurity using clinical fundus screening; 2. patients at the initial stage of treatment whose one eye at least has the following condition: stage 1+, stage 2+, stage 3, stage 3+ in zone 1; or stage 2+, stage 3+ in zone 2; or those with ap-rop according to the international rop classification,; 3. patient for whom the first treatment is laser therapy, intravitreal injection of conbercept or ranibizumab; exclusion criteria: 1. patients with neurological diseases that seriously affect visual function; 2. patient or his mother (during pregnancy) has received intravitreal or systemic anti-vegf drug therapy for other diseases; elimination criteria: 1. patients with insufficient data on treatment or medication; 2. patients who are followed up for less than 3 months after treatment.